Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CCNB1
REST API REST API
Homo sapiens
CCNB1 is differentially expressed in 339 experiments: 112 organism parts: bone marrow, blood, ... (110 more);, 258 disease states: normal, breast carcinoma, ... (256 more);, 111 cell types 387 cell lines 32 compound treatments and 82 other conditions.
Synonyms CCNB
Orthologs CCNB1 (2 of 2) (Danio rerio)   Ccnb1 (Rattus norvegicus)   CLB5 (Saccharomyces cerevisiae)   ccnb1 (Danio rerio)   CCNB1_BOVIN (Bos taurus)   CLB3 (Saccharomyces cerevisiae)   CLB2 (Saccharomyces cerevisiae)   CLB6 (Saccharomyces cerevisiae)   CLB1 (Saccharomyces cerevisiae)   Ccnb1 (Mus musculus)   CLB4 (Saccharomyces cerevisiae)   CycB (Drosophila melanogaster)   ccnb1 (Xenopus laevis)   ENSCAFG00000001107 (Canis familiaris)   XM_845305.1 (Canis familiaris)   ENSCAFG00000017961 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, spindle pole, histone phosphorylation, cell division, protein binding, cytoskeleton, cytoplasm, response to toxin, mitotic cell cycle, regulation of cyclin-dependent protein kinase activity, response to DDT, spermatogenesis, protein complex assembly, membrane fraction, soluble fraction, anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process, mitotic prometaphase, tissue regeneration, mitotic metaphase plate congression, positive regulation of mitotic cell cycle, microtubule organizing center, regulation of cell cycle, protein kinase binding, G1/S transition of mitotic cell cycle, nucleus, G2/M transition of mitotic cell cycle, oocyte maturation, kinase activity, mitotic spindle stabilization, response to drug, nucleoplasm, cell cycle checkpoint, negative regulation of gene expression, response to mechanical stimulus, digestive tract development, in utero embryonic development, histone kinase activity, cellular response to hypoxia, regulation of chromosome condensation, cellular response to fatty acid, positive regulation of histone phosphorylation, cellular response to iron(III) ion, positive regulation of mRNA 3'-end processing, positive regulation of attachment of spindle microtubules to kinetochore, mitotic cell cycle spindle checkpoint, positive regulation of cardiac muscle cell proliferation, ventricular cardiac muscle cell development, protein phosphorylation, negative regulation of protein phosphorylation, condensed nuclear chromosome outer kinetochore, positive regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle, cellular response to organic cyclic compound, regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle
InterPro Term Cyclin-like, Cyclin_N, Cyclin_C, Cyclin_A/B/D/E
UniProt Accession Q9BPX9, Q5TZP9, D6RHI0, P14635, E9PC90
Search EB-eye ENSG00000134057
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, ... (36 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-19397, E-GEOD-4717, ... (39 experiments)

Factor Value U/D Experiments
HL-60
4
E-GEOD-5258, E-MTAB-37, E-GEOD-24147, E-GEOD-96
MCF-7
4
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
BT-474
2
E-GEOD-3529, E-GEOD-5823
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HepG2
2
E-GEOD-21154, E-MTAB-37
PC3
2
E-GEOD-5258, E-MEXP-2034
381 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (49 experiments)

Factor Value U/D Experiments
monocyte
4
E-MEXP-583, E-GEOD-8286, E-GEOD-5099, E-GEOD-7307
CD8+ T cell
3
E-AFMX-5, E-TABM-145, E-MTAB-25
plasma cell
2
E-MEXP-2360, E-GEOD-6691
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
centroblast
2
E-TABM-702, E-GEOD-15271
105 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-TABM-15, ... (74 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-62, E-GEOD-3726, E-MTAB-57
lung adenocarcinoma
3
E-GEOD-2514, E-MTAB-62, E-MEXP-231
breast carcinoma
1
3
E-MTAB-37, E-TABM-276, E-GEOD-5823, E-GEOD-7307
prostate carcinoma
2
E-GEOD-96, E-MEXP-2034
cervical carcinoma
2
E-MTAB-62, E-GEOD-5823
choriocarcinoma
2
E-MTAB-62, E-MTAB-37
252 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-5741, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (24 experiments)

Factor Value U/D Experiments
platelet-derived growth factor
1
E-GEOD-1923
MIG control
1
E-GEOD-15811
ox-LDL
1
E-GEOD-5741
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
HMB-PP (phosphoantigen)
1
1
E-MEXP-1601
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
26 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
31
1
1
E-GEOD-21653


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-4619, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

crosslinker and crosslinking wavelength
studied in E-GEOD-21918

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-1638, E-GEOD-20033, E-MEXP-2359, ... (10 experiments)

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-17476, E-MEXP-421, E-GEOD-22593, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-2657, E-GEOD-10315, E-TABM-440, E-GEOD-837, E-GEOD-1692, ... (17 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-2748

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-GEOD-16363, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-MEXP-561, E-GEOD-6802

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (8 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-7307, E-GEOD-16363

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-1561, E-GEOD-6532, ... (7 experiments)

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.257 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM